Replies to post #163171 on Biotech Values

[DewDiligence]

I don’t understand why EMA permits duplicate dossiers, which create more work for the Agency and open up the possibility of an intended discrepancy. It would be seem to be a simple matter to allow two brand names under a single dossier, as the FDA did, for instance, with Procrit and Epogen.